Xromi 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0020/G 
This was an application for a group of variations. 
03/03/2023 
n/a 
B.II.e.2.z - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Other variation 
B.II.e.7.b - Change in supplier of packaging 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
PSUSA/1692/
Periodic Safety Update EU Single assessment - 
12/01/2023 
n/a 
PRAC Recommendation - maintenance 
202206 
hydroxycarbamide (for centrally authorised product 
only) 
IAIN/0018/G 
This was an application for a group of variations. 
09/01/2023 
06/02/2023 
SmPC, 
Labelling and 
PL 
B.IV.1.a.1 - Change of a measuring or administration 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
B.IV.1.a.1 - Change of a measuring or administration 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
B.IV.1.a.1 - Change of a measuring or administration 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
IA/0017 
B.II.b.5.b - Change to in-process tests or limits 
22/11/2022 
n/a 
applied during the manufacture of the finished 
product - Addition of a new test(s) and limits 
IAIN/0016 
B.IV.1.a.1 - Change of a measuring or administration 
10/10/2022 
n/a 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0014 
A.7 - Administrative change - Deletion of 
01/06/2022 
06/02/2023 
Annex II and 
manufacturing sites 
PL 
IA/0013/G 
This was an application for a group of variations. 
02/05/2022 
n/a 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
IB/0012 
C.I.11.z - Introduction of, or change(s) to, the 
02/05/2022 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0011 
C.I.z - Changes (Safety/Efficacy) of Human and 
24/03/2022 
n/a 
To provide an updated  study of ready biodegradability 
Veterinary Medicinal Products - Other variation 
according to OECD 301 
IB/0010 
C.I.11.z - Introduction of, or change(s) to, the 
28/02/2022 
06/02/2023 
Annex II 
To provide an updated RMP to implement the changes 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
required as a result of the Assessment of the 1st PSUR, 
EMEA/H/C/PSUSA/00001692/202006 for the Risk 
Management Plan of Xromi 100 mg/ml oral solution. 
PSUSA/1692/
Periodic Safety Update EU Single assessment - 
13/01/2022 
n/a 
PRAC Recommendation - maintenance 
202106 
hydroxycarbamide (for centrally authorised product 
only) 
IB/0008 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
22/11/2021 
14/02/2022 
SmPC 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment done under A 45/46 - Other variation 
PSUSA/1692/
Periodic Safety Update EU Single assessment - 
28/01/2021 
15/04/2021 
SmPC 
Refer to Scientific conclusions and grounds recommending 
202006 
hydroxycarbamide (for centrally authorised product 
the variation to terms of the Marketing Authorisation(s)’ for 
only) 
PSUSA/1692/202006. 
IB/0005 
C.I.z - Changes (Safety/Efficacy) of Human and 
01/04/2021 
n/a 
Veterinary Medicinal Products - Other variation 
IA/0007 
A.7 - Administrative change - Deletion of 
03/03/2021 
14/02/2022 
Annex II and 
manufacturing sites 
PL 
IAIN/0006 
B.II.b.2.c.1 - Change to importer, batch release 
02/02/2021 
14/02/2022 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IA/0004 
B.III.1.a.2 - Submission of a new/updated or 
16/12/2020 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IAIN/0003 
C.I.11.a - Introduction of, or change(s) to, the 
04/11/2020 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
wording agreed by the competent authority 
IA/0001 
B.II.b.4.a - Change in the batch size (including batch 
31/01/2020 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 5/5 
 
 
 
 
 
 
 
